Short Interest Don’t Lie: It Seems Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Will Go Up. Just Reported Less Shorted Shares

November 29, 2016 - By Winifred Garcia   ·   0 Comments

Short Interest Don't Lie: It Seems Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) Will Go Up. Just Reported Less Shorted Shares

The stock of Colucid Pharmaceuticals Incorporated (NASDAQ:CLCD) registered a decrease of 18.55% in short interest. CLCD’s total short interest was 581,500 shares in November as published by FINRA. Its down 18.55% from 713,900 shares, reported previously. With 225,600 shares average volume, it will take short sellers 3 days to cover their CLCD’s short positions. The short interest to Colucid Pharmaceuticals Incorporated’s float is 6.9%. About 256,344 shares traded hands or 3.68% up from the average. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has risen 384.29% since April 26, 2016 and is uptrending. It has outperformed by 379.03% the S&P500.

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The company has a market cap of $633.43 million. The Firm is engaged in developing a small molecule for the acute treatment of migraine headaches. It currently has negative earnings. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Ratings Coverage

Out of 2 analysts covering CoLucid Pharmaceuticals (NASDAQ:CLCD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. CoLucid Pharmaceuticals has been the topic of 4 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) earned “Buy” rating by William Blair on Friday, August 14. The stock has “Buy” rating given by Stifel Nicolaus on Monday, October 24. Stifel Nicolaus maintained CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) rating on Monday, September 19. Stifel Nicolaus has “Buy” rating and $30 price target. The firm has “Hold” rating given on Thursday, September 3 by Zacks.

CLCD Company Profile

CoLucid Pharmaceuticals, Inc., incorporated on August 31, 2005, is a Phase III clinical-stage biopharmaceutical company. The Firm is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain.

More notable recent CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 26, 2015, also Fool.com with their article: “Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday” published on September 15, 2016, Globenewswire.com published: “CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock” on September 09, 2016. More interesting news about CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) were released by: Prnewswire.com and their article: “CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred …” published on January 13, 2015 as well as Quotes.Wsj.com‘s news article titled: “News CoLucid Pharmaceuticals Inc.CLCD” with publication date: April 24, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>